摘要
目的:研究金复康口服液对支气管鳞状细胞癌患者近期疗效、生存质量及血清基质金属蛋白酶-9(MMP-9)水平的影响。方法:支气管鳞状细胞癌患者45例随机分为常规治疗组(A组,n=23)及常规治疗+金复康口服液组(B组,n=22),观察两组近期疗效(有效率)、患者生存质量(QLQ-LC13量表)及血清MMP-9水平。结果:B组治疗后有效率高于A组约33.60%(P<0.05),QLQ-LC13量表评分下降均大于A组(P<0.05),血清MMP-9水平下降显著高于A组[(11.57±3.26)ng/mL vs.(14.32±3.72)ng/mL](P<0.05)。结论:在常规治疗支气管鳞状细胞癌基础上加用金复康口服液能提高疗效,改善患者生存质量,同时可降低血清MMP-9水平。
Objective: To explore effect of Jinfukang oral liquid on patients with bronchial squamous carcinoma(BSC) and on serum level of matrix metallopeptidase-9(MMP-9).Methods: Forty-five BSC patients were enrolled and randomly assigned to regular group(Group A,n=23) or regular plus Jinfukang oral liquid group(Group B,n=22).Effective rate(ER),quality of life(QOL) and serum MMP-9 levels were assessed.Results: Patients in group B had significantly higher ER(33.59%) than patients in group A(P〈0.05).Similarly,the decrease of QOL scores and serum MMP-9 level [(11.57±3.26) ng/mL vs.(14.32±3.72) ng/mL] in group B were more significant(P〈0.05).Conclusions:Combining treatment of Jinfukang oral liquid and standard treatment can decrease MMP-9 level,and improve therapeutical effect and life quality.
出处
《海南医学院学报》
CAS
2012年第8期1061-1063,共3页
Journal of Hainan Medical University
基金
中国高校医学期刊临床专项资金项目(112210268)~~